PY Genrone Intermediates (P) Ltd, an innovator in active pharmaceutical ingredients (APIs) intermediates, has opened a pilot plant and R&D centre in Gujarat. Despite being known as the pharma capital of the world, India has historically relied on imports for critical pharmaceutical raw materials. Recognizing this gap, PY Genrone, founded in 2021 is set to empower India’s API independence.
Through the state-of-the-art pilot plant and R&D centre the company aims to develop solutions for various therapeutic areas, from cardiovascular to metabolic diseases, ultimately redefining bulk drug production in India. PY Genrone remains committed to offering customised solutions to cater to its clients’ specific needs.
Siddhartha Gupta, Founder and Managing Director, PY Genrone Intermediates (P) Ltd commented, “The brand through its cutting-edge solutions for both India and the world is taking steps in the mission to become a global leader in specialty chemicals. We’re getting ready to start up our commercial plant and introduce our products to the industry soon. This plant is the heart of our production, where we’ll be generating revenue. While our R&D and pilot plants contribute, it’s the commercial plant where our mission truly takes shape, bringing us one step closer to realizing this future, one breakthrough at a time”.
